Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Co.'s primary product candidate etripamil is a calcium channel blocker that it designed as a nasal spray. Co. is developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation and rapid ventricular rate and other cardiovascular indications. Co. has initiated a pivotal Phase 3 clinical trial (NODE-301) to assess etripamil in the at-home setting. Co. has completed a second Phase 1 clinical trial, further characterizing the pharmacokinetics and pharmacodynamic of etripamil in Japanese and non-Japanese healthy volunteers. The MIST stock yearly return is shown above.
The yearly return on the MIST stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MIST annual return calculation with any dividends reinvested as applicable (on ex-dates).
|